A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)

被引：0
|
作者：
Roche Kapoor
Matthew P. Deek
Riley McIntyre
Natasha Raman
Megan Kummerlowe
Iyah Chen
Matt Gaver
Hao Wang
Sam Denmeade
Tamara Lotan
Channing Paller
Mark Markowski
Michael Carducci
Mario Eisenberger
Tomasz M. Beer
Daniel Y. Song
Theodore L. DeWeese
Jason W. Hearn
Stephen Greco
Curtiland DeVille
Neil B. Desai
Elisabeth I. Heath
Stanley Liauw
Daniel E. Spratt
Arthur Y. Hung
Emmanuel S. Antonarakis
Phuoc T. Tran
机构：
[1] Sidney Kimmel Comprehensive Cancer Center,Department of Radiation Oncology and Molecular Radiation Sciences
[2] Johns Hopkins Hospital,Department of Medical Oncology
[3] Sidney Kimmel Comprehensive Cancer Center,The James Buchanan Brady Urological Institute and Department of Urology
[4] Johns Hopkins Hospital,Department of Pathology
[5] Johns Hopkins University School of Medicine,OHSU Knight Cancer Institute
[6] Johns Hopkins University School of Medicine,Department of Radiation Oncology
[7] Oregon Health & Science University,Department of Radiation Oncology
[8] University of Michigan,Karmanos Cancer Institute, Department of Oncology
[9] University of Texas Southwestern Medical Center,Department of Radiation Oncology and Cellular Oncology
[10] Wayne State University School of Medicine,Department of Radiation Medicine
[11] University of Chicago,undefined
[12] OHSU Knight Cancer Institute,undefined
[13] Oregon Health & Science University,undefined
来源：
BMC Cancer | / 19卷
关键词：
Recurrent prostate cancer; Salvage radiation therapy (SRT); High-risk prostate cancer; Enzalutamide; Prostatectomy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] The PRESIDE trial: A randomized, double-blind, placebo-controlled phase III efficacy and safety study of continued enzalutamide plus docetaxel after disease progression on enzalutamide alone in patients with metastatic castration-resistant prostate cancer.
    Chowdhury, Simon
    Davidson, Richard
    Coppell, Alex
    Mobasheri, Hossein
    Stari, Anny
    Snijder, Robert
    Treadwell, Cecil
    Merseburger, Axel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [42] A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer
    A J Pantuck
    C A Pettaway
    R Dreicer
    J Corman
    A Katz
    A Ho
    W Aronson
    W Clark
    G Simmons
    D Heber
    Prostate Cancer and Prostatic Diseases, 2015, 18 : 242 - 248
  • [43] A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer
    Pantuck, A. J.
    Pettaway, C. A.
    Dreicer, R.
    Corman, J.
    Katz, A.
    Ho, A.
    Aronson, W.
    Clark, W.
    Simmons, G.
    Heber, D.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2015, 18 (03) : 242 - 248
  • [44] Vandetanib Plus Fulvestrant Versus Placebo Plus Fulvestrant After Relapse or Progression on an Aromatase Inhibitor in Metastatic ER-Positive Breast Cancer (FURVA): A Randomised, Double-Blind, Placebo-Controlled, Phase II Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (11) : 18 - 19
  • [45] PROSPER: A Phase 3, Randomized, Double-Blind, Placebo (PBO)-Controlled Study of Enzalutamide (ENZA) in Menwith Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
    Stockler, M. R.
    Hussain, M.
    Fizazi, K.
    Saad, F.
    Rathenborg, P.
    Shore, N.
    Demirhan, E.
    Modelska, K.
    Phung, D.
    Krivoshik, A.
    Sternberg, C. N.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 53 - 54
  • [46] Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER -positive breast cancer (FAKTION): A randomized, double-blind, placebo-controlled, phase II trial.
    Jones, Robert Hugh
    Carucci, Margherita
    Casbard, Angela Claire
    Butler, Rachel
    Alchami, Fouad
    Bale, Catherine Jane
    Bezecny, Pavel
    Joffe, Johnathan
    Moon, Sarah
    Twelves, Chris
    Venkitaraman, Ramachandran
    Waters, Simon
    Howell, Sacha Jon
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [47] Capivasertib (AZD5363) Plus Fulvestrant Versus Placebo Plus Fulvestrant After Relapse or Progression on an Aromatase Inhibitor in Metastatic ER-Positive Breast Cancer (Faktion): a Randomized, Double-Blind, Placebo-Controlled, Phase II Trial
    Tio, Joke
    Kokornaczyk, Artur
    Tschalener, Bjoern
    Jones, Rober Hugh
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 9 - 9
  • [48] Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase III KEYNOTE-826 study
    Colombo, N.
    Dubot, C.
    Lorusso, D.
    Caceres, V.
    Hasegawa, K.
    Shapira-Frommer, R.
    Tewari, K. S.
    Salman, P.
    Hoyos, E.
    Yanez, E.
    Gumus, M.
    De Mendoza, M. Olivera Hurtado
    Samouelian, V.
    Castonguay, V.
    Arkhipov, A.
    Toker, S.
    Li, K.
    Keefe, S. M.
    Monk, B. J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1307 - S1308
  • [49] Results of a phase II trial of neoadjuvant abiraterone plus prednisone plus enzalutamide plus leuprolide (APEL) versus enzalutamide plus leuprolide (EL) for patients with high-risk localized prostate cancer (PC) undergoing radical prostatectomy (RP).
    McKay, Rana R.
    Xie, Wanling
    Lis, Rosina
    Ye, Huihui
    Zhang, Zhenwei
    Quoc-Dien Trinh
    Chang, Steven Lee
    Harshman, Lauren Christine
    Ross, Ashley
    Pienta, Kenneth J.
    Lin, Daniel W.
    Ellis, William J.
    Montgomery, Robert B.
    Chang, Peter
    Wagner, Andrew
    Bubley, Glenn
    Kibel, Adam S.
    Taplin, Mary-Ellen
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [50] Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer
    Karlan, Beth Y.
    Oza, Amit M.
    Richardson, Gary E.
    Provencher, Diane M.
    Hansen, Vincent L.
    Buck, Martin
    Chambers, Setsuko K.
    Ghatage, Prafull
    Pippitt, Charles H., Jr.
    Brown, John V., III
    Covens, Allan
    Nagarkar, Raj V.
    Davy, Margaret
    Leath, Charles A., III
    Hoa Nguyen
    Stepan, Daniel E.
    Weinreich, David M.
    Tassoudji, Marjan
    Sun, Yu-Nien
    Vergote, Ignace B.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04) : 362 - 371
12345